SCHULMAN AMY W

Director Amy W Schulman purchases 8,550 shares of GUTS at $1.17 amid -83.7% 52-week decline; 4-insider cluster buy.

Director Amy W Schulman purchased 8,550 shares at $1.17 on 2025-03-13 while the stock trades at $1.27 in a severely depressed valuation context: the stock is -83.7% from its 52-week high and down -37.0% over 90 days. The company is structurally unprofitable (net income $-23.2M on revenue $14.0K in the latest quarter) with revenue declining -22.5% year-over-year, indicating deteriorating fundamental performance. This purchase occurs within a cluster of 4 other insider buys in the past 14 days, which may signal internal recognition of value at current prices, but given the steep decline, extended losses, and shrinking revenue base, the transaction requires examination of whether this represents conviction or responds to specific liquidity or obligation factors. Schulman's prior cross-ticker open-market history shows 4 sales with 90d well-timed rate of 0.00%, indicating no historical pattern of well-timed exit execution that would lend confidence to her ability to identify attractive entry points.

10% Owner Polaris Management Co. VII acquires 909,090 CAMP shares at $11.00 ($10.0M); 6 insiders also bought within 14 days

Polaris Management Co. VII, a 10% owner, purchased 909,090 shares at $11.00 on 2024-10-15 for a total value of $9,999,990.00, establishing a new position of 909,090 shares post-transaction. Notably, 6 other insiders also bought within the past 14 days, forming a cluster buy pattern that suggests broad insider confidence in the company's near-term direction. The current stock price of $10.75 sits at the 52-week high (range $0.40–$10.75), indicating the buy occurred near recent peak valuations with limited upside from transaction price. This synchronized multi-insider buying activity—despite elevated price levels—warrants investor attention to the underlying catalysts that motivated the coordinated accumulation.

Director Amy W Schulman sold 8,500 shares of ALNY for $2,040,000 on 2024-06-25 under pre-arranged 10b5-1 plan.

Amy W Schulman, a director at Alnylam Pharmaceuticals, sold 8,500 shares at $240.00 per share for a total value of $2,040,000.00 on 2024-06-25 pursuant to a pre-arranged 10b5-1 trading plan adopted on 2024-02-28. This sale reduced her holdings from 16,936 shares to 8,436 shares, representing a net change of sold 8,500 shares (-50.2% vs pre-transaction holdings). Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects a predetermined execution schedule established in February 2024, not a contemporaneous trading decision. The sale disposed of approximately half her stated holdings, but the scheduled nature precludes attribution of timing-based signaling.